415 results on '"Kinney W"'
Search Results
152. LETTERS.
153. A Short Formal Synthesis of Squalamine from a Microbial Metabolite
154. Synchronous adjuvant chemoradiation after extended hysterectomy and lymphadenectomy for patients with figo IB cancer of the cervix metastatic to pelvic nodes
155. Bipolar and unipolar tests of 1.5 m model SSC collider dipole magnets at Fermilab.
156. Tests of 40 mm SSC dipole model magnets with vertically split yokes.
157. Tests of 1.5 meter model 50 mm SSC collider dipoles at Fermilab.
158. PROVINCE OF QUEBEC AND VERMONT CONFERENCE.
159. FLORIDA.
160. ChemInform Abstract: Efficient Route to 7α-(Benzoyloxy)-3-dioxolane Cholestan-24(R)-ol, a Key Intermediate in the Synthesis of Squalamine.
161. ChemInform Abstract: Synthesis of 24ξ-Squalamine, an Antiinfective Steroidal Polyamine.
162. ChemInform Abstract: Stereoselective Synthesis of Squalamine Dessulfate.
163. Surface statistics and the spatial coherence of surface-scattered energy.
164. ChemInform Abstract: Synthesis of Alkyl Substituted Cyclobutenediones by Free Radical Chemistry. Carbon for Nitrogen Replacement in the α-Amino Acid Bioisoster. 3,4-Diamino-3-cyclobutene-1,2-dione.
165. 3-Hydroxy-3-cyclobutene-1,2-dione: application of a novel carboxylic acid bioisostere to an in vivo active non-tetrazole angiotensin II antagonist
166. Methacholine responsiveness after multiple antigen challenges
167. Brief exposure to a novel environment enhances binding of hippocampal transcription factors to their DNA recognition elements
168. Reduce completion fluid costs with on-site brine tests
169. CMB polarization constraints on inflation
170. Constraining inflation with cosmic microwave background polarization
171. Nitrogen neutron elastic and inelastic scattering cross sections from 4.34 to 8.56 MeV
172. DESCRIPTION AND OPERATING MANUAL FOR THE THREE GROUP, THREE REGION REACTOR CODE FOR ORACLE
173. MODIFICATION AND FURTHER DEVELOPMENT OF THE NUCLEON TRANSPORT CODE, NTC.
174. TEST OF NEUTRON TOTAL CROSS-SECTION EVALUATIONS FROM 0.2 TO 20 MeV FOR C, O, Al, Si, Ca, Fe, AND SiO .
175. STAINLESS STEEL UNIVERSITY REACTOR
176. INVESTIGATIONS ON Cs$sup 137$ (thesis)
177. EXPERIMENTS AND CALCULATIONS ON UNMODERATED URANIUM-MOLYBDENUM ALLOY CRITICAL ASSEMBLIES
178. CALCULATED FLUXES OF LESS THAN 50-Mev NEUTRONS DIFFUSING BENEATH THE SHIELD OF A MESON PRODUCTION FACILITY
179. CALCULATED TISSUE CURRENT-TO-DOSE CONVERSION FACTORS FOR NUCLEONS BELOW 400 Mev
180. NEUTRON ELASTIC AND INELASTIC SCATTERING FROM $sup 56$Fe FROM 4.60 TO 7.55 MeV.
181. NTC: A TRANSPORT CODE FOR PROTONS AND NEUTRONS OF ENERGY UP TO 400 Mev
182. SOME TESTS OF COVEYOU'S ANISOTROPIC SELECTION TECHNIQUE
183. FINITE-SAMPLE CORRECTIONS TO NEUTRON SCATTERING DATA.
184. Cancers within 3years of an ASC HPV test negative result.
185. A MONTE CARLO CALCULATION OF SCATTERED NEUTRON FLUXES AT AN AIR-GROUND INTERFACE DUE TO POINT ISOTROPIC SOURCES ON THE INTERFACE
186. CARBON NEUTRON ELASTIC- AND INELASTIC-SCATTERING CROSS SECTIONS FROM 4.5 TO 8.5 MeV.
187. CALCULATED FLUXES OF LESS THAN 50-Mev NEUTRONS DIFFUSING BENEATH THE SHIELD OF A MESON PRODUCTION FACILITY
188. PROGRAM STATEST, AN APPLICATION OF THE METHOD OF STATISTICAL ESTIMATION TO THE CALCULATION OF NEUTRON FLUX IN ANISOTROPICALLY SCATTERING MEDIA BY MONTE CARLO
189. $sup 60$Ni NEUTRON ELASTIC- AND INELASTIC-SCATTERING CROSS SECTIONS FROM 6.5 TO 8.5 MeV.
190. CALCIUM NEUTRON ELASTIC- AND INELASTIC-SCATTERING CROSS SECTIONS FROM 4.0 TO 8.5 MeV.
191. SULFUR NEUTRON ELASTIC- AND INELASTIC-SCATTERING CROSS SECTIONS FROM 4.0 TO 8.5 MeV.
192. NEUTRON ELASTIC- AND INELASTIC-SCATTERING CROSS SECTIONS FOR Na IN THE RANGE OF 5.4 TO 8.4 MeV.
193. Lessons from practice: Risk of cancer associated with cervical intraepithelial neoplasia 2 (CIN2) or cervical intraepithelial neoplasia 2/3 (CIN2/3) in women 21–24 and 25–29 followed without excisional treatment for a minimum of 18months.
194. HPV16 methylation is a consistent biomarker of cervical intraepithelial neoplasia (CIN) 3 using a novel next-generation bisulfite-sequencing technology.
195. Pap-negative, human papillomavirus-positive screening results: Compliance with follow-up and results of follow-up
196. Cervical cancer rates in clinical practice with co-testing, interval extension and current evaluation of women with pap-negative, human papillomavirus-positive screening tests
197. KLS-13019, a Novel Structural Analogue of Cannabidiol and GPR55 Receptor Antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy in Rats.
198. Population-Based Incidence of Cervical Intraepithelial Neoplasia Across 14 Years of HPV Vaccination.
199. Primary human papillomavirus testing vs cotesting: clinical outcomes in populations with different disease prevalence.
200. Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.